TransCode Therapeutics's total assets for Q4 2025 were $162.40M, an increase of 3007.11% from the previous quarter. RNAZ total liabilities were $10.52B for the fiscal quarter, a 276656.35% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.